BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ChamberMaster//Event Calendar 2.0//EN
METHOD:PUBLISH
X-PUBLISHED-TTL:P1H
REFRESH-INTERVAL:P1H
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
DTSTART:20070101T000000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:Eastern Daylight Time
END:DAYLIGHT
BEGIN:STANDARD
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
DTSTART:20070101T000000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:Eastern Standard Time
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261216T110000
DTEND;TZID=America/New_York:20261216T120000
X-MICROSOFT-CDO-ALLDAYEVENT:FALSE
SUMMARY:AMERSA Advocacy Webinar: Methadone Access Reform: Clinical\, Community\, and Lived-Experience Perspectives on MOTAA 2.0
DESCRIPTION:For more than 50 years\, people with opioid use disorder in the U.S. have been able to get methadone only through opioid treatment programs\, often with near-daily visits. The bipartisan Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0)\, reintroduced in June 2026\, would let board-certified addiction specialists prescribe methadone for OUD and let community pharmacies dispense it. It would also let HHS approve more types of prescribers without new legislation. What would this change for patients\, and who might still be left behind? Join a pharmacist\, a physician-researcher\, a community-engaged scientist\, and an advocate with lived experience of methadone treatment for a candid conversation about the bill\, the current regulations\, and the resources and practical steps clinicians\, researchers\, and advocates can use to expand access now.
X-ALT-DESC;FMTTYPE=text/html:For more than 50 years\, people with opioid use disorder in the U.S. have been able to get methadone only through opioid treatment programs\, often with near-daily visits. The bipartisan Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0)\, reintroduced in June 2026\, would let board-certified addiction specialists prescribe methadone for OUD and let community pharmacies dispense it. It would also let HHS approve more types of prescribers without new legislation. What would this change for patients\, and who might still be left behind? Join a pharmacist\, a physician-researcher\, a community-engaged scientist\, and an advocate with lived experience of methadone treatment for a candid conversation about the bill\, the current regulations\, and the resources and practical steps clinicians\, researchers\, and advocates can use to expand access now.
LOCATION:
UID:e.4288.1674976
SEQUENCE:3
DTSTAMP:20261104T045120Z
URL:https://members.amersa.org/events/Details/amersa-advocacy-webinar-methadone-access-reform-clinical-community-and-lived-experience-perspectives-on-motaa-2-0-1973448?sourceTypeId=Hub
END:VEVENT
END:VCALENDAR